MedComm (Jul 2024)

Nanoliposomes as nonviral vectors in cancer gene therapy

  • Safiye Nur Yildiz,
  • Maliheh Entezari,
  • Mahshid Deldar Abad Paskeh,
  • Sepideh Mirzaei,
  • Alireza Kalbasi,
  • Amirhossein Zabolian,
  • Farid Hashemi,
  • Kiavash Hushmandi,
  • Mehrdad Hashemi,
  • Mehdi Raei,
  • Mohammad Ali Sheikh Beig Goharrizi,
  • Amir Reza Aref,
  • Ali Zarrabi,
  • Jun Ren,
  • Gorka Orive,
  • Navid Rabiee,
  • Yavuz Nuri Ertas

DOI
https://doi.org/10.1002/mco2.583
Journal volume & issue
Vol. 5, no. 7
pp. n/a – n/a

Abstract

Read online

Abstract Nonviral vectors, such as liposomes, offer potential for targeted gene delivery in cancer therapy. Liposomes, composed of phospholipid vesicles, have demonstrated efficacy as nanocarriers for genetic tools, addressing the limitations of off‐targeting and degradation commonly associated with traditional gene therapy approaches. Due to their biocompatibility, stability, and tunable physicochemical properties, they offer potential in overcoming the challenges associated with gene therapy, such as low transfection efficiency and poor stability in biological fluids. Despite these advancements, there remains a gap in understanding the optimal utilization of nanoliposomes for enhanced gene delivery in cancer treatment. This review delves into the present state of nanoliposomes as carriers for genetic tools in cancer therapy, sheds light on their potential to safeguard genetic payloads and facilitate cell internalization alongside the evolution of smart nanocarriers for targeted delivery. The challenges linked to their biocompatibility and the factors that restrict their effectiveness in gene delivery are also discussed along with exploring the potential of nanoliposomes in cancer gene therapy strategies by analyzing recent advancements and offering future directions.

Keywords